Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Schering-Plough: Approval of OTC Claritin expected to fully deplete trade inventories of Rx version by end of 2002, leading to "negative impact on pretax profits" of approximately $250 mil., company says April 18. Negative financial effect may be partially offset by trade inventory build-up of OTC loratadine, Rx Clarinex, firm says. Worldwide Claritin sales declined 8% to $659 mil. in Q1 due, in part, to conversion of patients to Clarinex. Sun care sales rose 7.9% to $82 mil., while foot care sales were flat at $76 mil. OTC revenue declined 24% to $41 mil. due to "manufacturing issues." Consolidated Q1 sales totaled $2.56 bil., up 10.8%, and net income rose 6.4% to $600 mil...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS093925

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel